Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.1800 (0.68%) ($4.9357 - $5.3004) on Fri. May. 24, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.66% (three month average) | RSI | 18 | Latest Price | $5.1800(0.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.5% a day on average for past five trading days. | Weekly Trend | HTBX declines -11.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) IGOV(12%) GDX(11%) GLD(11%) GDXJ(10%) SIL(9%) | Factors Impacting HTBX price | HTBX will decline at least -2.33% in a week (0% probabilities). VCSH(-10%) JETS(-5%) CEMB(-5%) IFRA(-3%) XLV(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.33% (StdDev 4.66%) | Hourly BBV | 0 () | Intraday Trend | -2.3% | | | |
|
1 - 5 Day Possible Target | $-15.93(-407.53%) | Resistance Level | $6.48 | 5 Day Moving Average | $5.54(-6.5%) | 10 Day Moving Average | $5.82(-11%) | 20 Day Moving Average | $6.48(-20.06%) | To recent high | -57.2% | To recent low | 0.7% | Market Cap | $570m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |